

# Targeted Inhibition of CDK5-mediated Regulation of Human Endogenous Retrovirus K (HML-2) Envelope Protein in Atypical Teratoid Rhabdoid Tumor


---

**Tara Doucet-O'Hare**<sup>1,2</sup>, Jared Rosenblum<sup>2</sup>, Brianna DiSanza<sup>1</sup>, Catherine DeMarino<sup>1</sup>, Nasir Malik<sup>3</sup>, Joseph Steiner<sup>3</sup>, Abigail Atkinson<sup>1</sup>, Harish Pant<sup>4</sup>, Zhengping Zhuang<sup>2</sup>, Avindra Nath<sup>1</sup>

<sup>1</sup>Section of Infection of the Nervous System, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD; <sup>2</sup>Neuro-oncology branch, National Cancer Institute (NCI); <sup>3</sup>Translational Neuroscience Center, NINDS, NIH, Bethesda, MD.

<sup>4</sup>Neuronal Cytoskeletal Protein Regulation Section, NINDS, NIH, Bethesda, MD.



# Human Endogenous Retrovirus K (HERV-K HML-2) Envelope (ENV) is expressed and released in AT/RT



Extracellular vesicles of multiple sizes undergo exocytosis from AT/RT cells




CD98 (putative receptor for HERV-K Env) colocalizes with HERV-K ENV

# Ouabain Decrease Cell Viability and HERV-K (HML-2) ENV expression





# CDK-5 is hyperactive in AT/RT, binds HERV-K ENV, and TP5 treatment leads to concentration dependent cell death



# Ouabain and TP5 affect HERV-K stability, sorting, and release

